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Summary 
 
Sleeping sickness and Chagas’ disease (African and American trypanosomiases, 
respectively) are protozoan parasitic diseases threatening millions of people in sub-
Saharan Africa and Latin America, respectively. Trypanosomiases are among the most 
neglected diseases in the world, lacking desperately from financial support for 
investigation. The current chemotherapy of both diseases is poor and suffers from 
intolerable side-effects and low efficacy in many cases. A review of the patent literature 
(2002-early 2005) claiming for molecules with   antitrypanosomal activity afforded 36 
entries, equally shared between industry and academia. Among the targets validated 
against trypanosomes, patents dealing with proteases inhibitors were the most 
represented (16 patents). Other targets claimed in the patent literature included 
membrane architecture (sterol biosynthesis inhibitors, protein farnesyltransferase 
inhibitors), DNA (DNA binders, tubulin inhibitors) and pyrimidine metabolism (CTP 
synthetase inhibitors). Natural products were also a great source of trypanocidal lead 
compounds (9 patents). A few patents claiming for compounds with antitrypanosomal 
activity but disclosing no specific target were also encountered. 
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1. Introduction 
Diseases caused by parasitic protozoa are of major impact in the third world. 
Parasitic protozoa belonging to the order kinetoplastida cause Chagas’ disease 
(American trypanosomiasis), sleeping sickness (Human African Trypanosomiasis or 
HAT) and leishmaniasis. HAT and Chagas’ disease are caused by protozoa of the genus 
Trypanosoma which are transmitted to the mammalian host by biting insect vectors, 
tsetse fly and triatomine bugs, respectively [1].  
Two species of trypanosomes are responsible of the chronic and acute form of 
HAT respectively, T. brucei gambiense and T. b. rhodesiense, whereas other species (T. 
b. brucei, T. congolense and T. vivax) cause animal trypanosomiasis (Nagana) in cattle. 
HAT is a resurgent disease in sub-Saharan Africa where it had almost disappeared in the 
1960’s following the systematic screening and treatment of millions of people at risk. 
Unfortunately, active population screening declined in the latter part of the twentieth 
century and the disease has re-emerged as a major health problem in recent years [2]. 
HAT is a daily threat to more than 60 million people in 36 countries of sub-Saharan 
Africa with prevalence of an estimated 500,000 infected individuals [2]. The disease is 
characterised by two pathological stages depending on the presence or not of parasites 
in the cerebrospinal fluid. In stage 1, parasites invade the bloodstream via the lymphatic 
system following infection of the host by the bite of an infected tsetse fly. This stage 
can last from a few weeks (rhodesiense sleeping sickness) to several years in the case of 
T. b. gambiense. When parasites invade the central nervous system (CNS), the disease is 
always fatal if left untreated [3]. 
Trypanosoma cruzi is responsible of Chagas’ disease which is one of the most 
prevalent infectious diseases infecting between 11-18 million of people in Central and 
South America. Recent efforts in the control of the vector and systematic screening of 
blood donors in endemic countries have led to a great decrease in transmission of the 
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disease over the past decade. The disease is characterised by two distinct stages: an 
acute phase of parasite growth and invasion of host cells follows the infection. Then, a 
chronic stage, often asymptomatic, in which the parasite installs inside target organs 
(gastrointestinal tract, heart) leads in about 15-30 % of patients to irreversible organ 
damage as late as 10-25 years after infection [4]. 
Chemotherapeutic drugs exist for both diseases; however none of them is fully 
satisfactory because of important side-effects and/or a lack of activity against CNS stage 
of sleeping sickness or against chronic Chagas’ disease. Two drugs are licensed for the 
chemotherapy of Chagas’ disease, namely nifurtimox (Lampit™, manufactured by 
Bayer) and benznidazole (Rochagan™, Radanil™, Roche) which are both 
nitroheterocyclic compounds active against circulating trypomastigotes (Figure 1). 
However, these drugs are hardly efficient against the chronic stage of the disease, 
possibly due to unfavourable pharmacokinetic properties, and their efficacy varies 
depending on the T. cruzi strains [5,6,7].  
Only four drugs are licensed for the treatment of HAT (Figure 1): Eflornithine 
(Ornidyl™; Bayer), suramin (Germanin™, Bayer), pentamidine (Lomidine™, Aventis) 
and melarsoprol (Mel B, Arsobal™, Aventis) although other drugs such as berenil 
(usually used against animal trypanosomiasis) or the nitrofuran nifurtimox have also 
proved useful in some limited cases [8,9,10]. These drugs are far from satisfactory 
because of major side effects, the parenteral mode of administration and unaffordable 
price for African countries. Moreover, some of those drugs (suramin, pentamidine) are 
unable to cross the blood-brain barrier (BBB) in sufficient quantity to treat late-stage 
cases of HAT. The increasing resistance to the arsenical melarsoprol [11,12], which is 
the main drug used to treat the late stage (when the CNS is affected) of both forms of 
the disease, has increased the need for alternative drugs. The long term availability of 
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the existing drugs is also compromised although pharmaceutical industries (i.e. Aventis 
and Bayer) signed an agreement with WHO in 2001 to guarantee their production for at 
least five years [1]. 
Despite many similarities between African and American trypanosomes, there are 
crucial differences, such as an intracellular existence for T. cruzi in the mammalian host 
whereas T. brucei remains exclusively extracellular [1]. These divergences have to be 
taken into account for drug design since chemotherapeutic agents meant to kill T. cruzi 
intracellular amastigotes will have to cross several cellular membranes to get to their 
target and drugs targeting the CNS stage of sleeping sickness must be able to cross the 
BBB.  
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Figure 1. Licensed antitrypanosomal drugs 
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 The rational approach to drug design has been applied to trypanosomes as these 
parasites have a number of unusual biochemical pathways [13]. Widely studied targets 
include enzymes of the glycolytic [14,15] and pentose phosphate pathway [16,17,18], 
trypanothione reductase [19,20], the polyamine pathway [21], 
glycosylphosphatidylinositol (GPI) biosynthesis and remodelling, and topoisomerases 
[22,23]. 
 
Despite many years of efforts in the search of new trypanocidal drugs (mainly by 
academia institutions), no new chemical entity has been registered for trypanosomiases 
since the approval of Eflornithine for the treatment of CNS gambiense sleeping sickness 
in 1990. Moreover, there is no perspective for the registration of new trypanocidal drugs 
in the near future and only one compound, the diamidine prodrug DB289 (see section 
2.3), is currently being studied in phase II clinical trials for the oral treatment of HAT 
[9,24,25,26].  
 A search in the patent literature for the period 2002-early 2005 for the claim of 
trypanocidal activity against T. brucei or T. cruzi parasites afforded 36 entries. 
However, only a small proportion of these patents displayed specific data of biological 
activity against these parasites. A few patents published in 2002 and claiming anti- T. 
cruzi activity which were previously reviewed by Urbina [27] were not included in this 
paper. This review is organised in three sections: in the first place, and representing two 
third of the entries, are the patents referring to specific drug targets such as proteases 
inhibitors, sterol biosynthesis inhibitors, protein farnesyl transferase inhibitors, DNA 
modulating agents and pyrimidine metabolism inhibitors. The second section refers to 
natural product derived chemotherapeutic agents and the third one to single synthetic 
entities. 
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2.  Drug targets 
2.1. Protease inhibitors 
Proteases are essential enzymes involved in the regulation of important 
functions of trypanosome life cycle. Cruzain (or cruzipain), is the major cysteine 
protease of T. cruzi and is expressed in all life cycle stages of the parasite. Rhodesain is 
a cysteine protease expressed in T. b. rhodesiense that regulates replication of the 
parasite. Various studies have shown that cruzain and rhodesain inhibitors block the 
parasite life cycle in vitro [28,29,30,31] and in vivo [32,33] and do not cause toxicity to 
the host. The crystal structure of cruzain bound to various inhibitors has been solved 
[34,35,36,37]. Hence, cysteine proteases inhibitors (CPI) represent excellent leads for 
the design of antitrypanosomal drugs. In addition, cruzain shares a significant homology 
(≈ 45%) in the amino acid sequence with the mammalian cathepsin L cysteine protease 
[38,39,40]. As a result, pharmaceutical companies that are interested in the design of 
CPI for the treatment of various cancers and bone diseases, also claim cruzain and/or 
rhodesain inhibitory activity in their patents dealing with CPI. The importance of CPI as 
a drug target is reflected by the number of patents disclosed by various pharmaceutical 
companies in the last five years: 16 patents for the 2002-2004 period (this review) and 7 
patents during the 1999-2002 period [27].  
In their search for cathepsin K inhibitors, SmithKline Beecham Corp. published 
several patents describing the syntheses and use of peptidomimetics based on an 
azepine [201,202,203,204,205] or thiazepane [206] template. As a whole, about 500 
new compounds were prepared and tested as cathepsin K inhibitors and claimed to be 
useful against different parasitic diseases including trypanosomiasis. However, only two 
patents [201,204] reported specific biological data. Four compounds had in vitro Ki 
values of 0.3 nM (1, Figure 2 and Table 1) to 1.8 nM against human Cathepsin K and 
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values of 69 to 926 nM against Cathepsin L, Cathepsin S and Cathepsin B when tested 
in protease catalytic activity assays [201]. The other patent disclosed the inhibition by 
4-aminoazepan-3-one derivatives of seven parasitic proteases, including cruzain, 
rhodesain, falcipain, leishmania B and L and schistosoma B1 and B2 enzymes. Among 
222 compounds tested, 43 had a Ki value < 5 nM against cruzain and 79 had a Ki < 5 
nM against rhodesain. The most potent CPI against rhodesain and cruzain were the 1-
(pyridin-2-ylsulfonyl)azepan-3-one derivatives 2 and 3, respectively (Table 1). Other 
peptidomimetics useful as CPI were reported by NAEJA Pharmaceuticals Inc. [207]. 
The preparation of 22 dihydropyrimidine derivatives was illustrated and the in vitro rat 
cathepsin B, L, K and S activity was disclosed (e.g. compound 4, Figure 2, Table 1). In 
2004, Amura Ltd (previous applications were assigned to Incenta Ltd [27]) published an 
application with the synthesis and cathepsin K activity of over 2000 bicyclic 
heterocycle compounds. The CP inhibitory activity was determined in four examples 
and compound 5 showed Ki value > 0.3 µM against cruzain and < 0.01 µM against 
human cathepsin K [208]. Other peptide-based CPI claimed by Dendreon San Diego 
LLC (exemplified by 6) were stated to have IC50 < 50 nM against cruzipain and 
falcipain. However, no specific biological data was presented [209]. Medivir UK Ltd 
also published an application with 27 amide-based CPI claimed to be useful for 
protozoal infections [210]. The in vitro cathepsin S, L and K inhibitory activity, and 
cathepsin K and falcipain proteolytic catalytic activity of 27 compounds (e.g. 7) were 
determined but no biological data was presented.  Over 450 novel nitrile compounds 
(e.g. 8) disclosed by Boehringer Ingelheim Pharmaceuticals Inc were claimed to be 
useful for the treatment of diseases mediated by cysteine proteases, specifically 
cathepsin K and S. The best compounds were stated to have IC50 values < 50 µM 
against cathepsin K and < 10 µM against cathepsin S, F, L and B although no detailed 
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results were included [211]. The National Research Council of Canada disclosed 
interesting propeptide-based non covalent CPIs designed to mimic the reverse binding 
mode, relative to the substrate, of the propeptides of these enzymes. The compounds 
were claimed to span both the S’ and S subsites of the enzyme active site and a 1.9Å X-
ray crystal structure of the complex of cathepsin L with one of the inhibitors confirmed 
this hypothesis. Ten compounds assayed against cruzain and rhodesain had Ki values 
from 0.09 (9) to 20 µM and from 0.3 (9) to 35 µM, respectively [212].  
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Figure 2. Peptide-based CPIs 
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Table 1. Enzymatic activity of CPIs 
Compound Enzyme tested IC50 (nM) Ki (nM) Reference 
 
1 
Human cathepsin K 
Human cathepsin L 
Human cathepsin S 
Human cathepsin B 
 
 
 
0.3 
69 
175 
173 
 
[201] 
 
2 
Rhodesain 
Cruzain 
Falcipain 
 0.93 
3.3 
3.1 
 
[204] 
 
3 
Rhodesain 
Cruzain 
Falcipain 
 2.1 
1.8 
4.4 
 
[204] 
 
4 
Rat cathepsin K 
Rat cathepsin L 
Rat cathepsin S 
Rat cathepsin B 
14 
170 
37 
420 
  
[207] 
5 Cruzain 
Human cathepsin K 
Human cathepsin L 
 > 300 
< 10 
> 3000 
 
[208] 
6 cruzipain, falcipain < 50  [209] 
7 cathepsin K, L, S, falcipain 2 ndpa ndp [210] 
8 Human cathepsin K 
Human cathepsin S, L, F, B 
< 50000 
< 10000 
 [211] 
 
 
9 
Cruzain 
Rhodesain 
Human cathepsin B 
Human cathepsin K 
Human cathepsin L 
 90 
300 
560 
1000 
67 
 
 
[212] 
10 Human cathepsin K  < 50 [213] 
11 Human cathepsin K 1.5  [214] 
12 Serine peptidase, cysteine protease,  
metalloprotease, endopeptidase 
ndp ndp [215] 
13 Plasmepsin II 18  [216] 
a no data provided 
 
 
Apart from the patent literature, new scaffolds of CPI are regularly described. For 
instance, Y. Choe and colleagues designed a series of α-keto-based peptide inhibitors of 
cruzain with picomolar potency in vitro, some of them showing antitrypanosomal 
activity in cell cultures. These peptidic covalent reversible inhibitors (Scheme 1a) which 
represent new scaffolds of CPI, have poor membrane permeability and would need to be 
optimised in order to display better activity [41]. Another interesting paper reports the 
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first crystal structure of non-covalent CPI bound to cruzain [37]. The same group also 
prepared libraries of cyclic ketone-based CPI with nanomolar Ki values [42,43].  
 
 
Scheme 1. Proposed mechanism for the interaction of reversible covalent CPIs with 
cruzain: a) α-keto-based peptide inhibitors [from ref 41]; b) thiosemicarbazones [from 
ref. 45] 
 
Non peptide CPIs were less represented in the patent literature for the 2002-
2004 period (Figure 3). An example of unusual structure useful against cruzain and 
rhodesain was the thiosemicarbazone scaffold described by the team of the University 
of California [44,45,46]. These compounds were proposed to work as reversible 
covalent inhibitors of the enzyme (Scheme 1b) [45]. Novartis AG described a series of 
over 100 novel heteroaryl nitrile derivatives (e.g. 10) having in vitro activity against 
recombinant human cathepsin K with Ki < 50 nM. No compound was specifically 
claimed and no biological data was provided [213]. Another series of 2-cyano-4-
aminopyrimidines CPIs was disclosed by this company in a patent describing the 
synthesis of over 90 compounds. Compound 11 had an IC50 = 1.5 nM in the inhibition 
of cathepsin K [214]. Other atypical CPI were the cyclopalladated 
bis(diphenylphosphine)-ferrocene compounds disclosed by the State of Sao Paulo 
Research Foundation in 2004 (e.g. 12). These derivatives were claimed to inhibit 
  13
enzymes of the serine peptidase, cysteine protease, metalloprotease and endopeptidase 
families and to be useful against the development and metastases of malignant tumors 
[215]. Finally, Actelion Pharmaceuticals described a series of amino-aza-cycloalkane 
derivative as inhibitors of aspartic proteases, particularly of the plasmodium falciparum 
plasmepsin II, useful against protozoal infections. Compound 13, which is one of 140 
derivatives disclosed, inhibited plasmepsin II with IC50 = 18 nM [216].  
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Figure 3. Non-peptide CPIs 
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2.2. Membrane architecture  
2.2.1. Sterol biosynthesis inhibitors 
The sterol biosynthetic pathway produces membrane lipids in all eukaryotic 
organisms. The singularity of this pathway in fungi and kinetoplastid parasites has been 
successfully exploited as a target for chemotherapy for many years [7,47,48] and several 
commercial and experimental antifungal azoles, inhibitors of sterol biosynthesis (e.g. 
ketoconazole, posaconazole, D0870), have been tested successfully against T. cruzi 
[27,49,50]. On the other hand, sterol biosynthetic pathway is unlikely to be a valid 
target for T. brucei bloodstream form trypomastigotes (the relevant form in sleeping 
sickness) that do not appear to synthesise their own sterols and scavenge them from the 
human host [51]. Squalene synthase [48,52,53,54,55], sterol 24-methyltransferase [56] 
or farnesylpyrophosphate synthase [57] are enzymes of the sterol biosynthetic pathway 
that are showing growing interest as antitrypanosomal targets against T. cruzi.  
The synthesis of 5-amino-1-benzyl-imidazole derivatives with distinctive anti-
bacterial, anti-fungal and antitrypanosomal activity was disclosed by Yale University 
[217]. These compounds were designed as inhibitors of C-14α-demethylase. This 
enzyme is a cytochrome P450 enzyme (P-45014DM) that catalyses the removal of the 
14α methyl carbon (C32) of lanosterol in the presence of molecular oxygen and 
NADPH. Since 14-methyl sterols cannot function within cell membranes, inhibition of 
P-45014DM represents a good target for chemotherapy. All of the compounds were tested 
against T. cruzi amastigotes (Tulahuen strain) grown on monolayer of mouse 3T3 
fibroblasts and were non toxic to these cells. The SAR study resulting from the analysis 
of 40 derivatives put into evidence the importance of hydrophobic substitution and para 
phenyl substitution (vs. ortho or meta) for better activity. EC50 values ranged from the 
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remarkable 500 pM (14, Figure 4) to 1 µM. However, these compounds had benzoate 
ester or amide moieties which could potentially be cleaved in vivo by esterase and 
proteases, affording the less potent free benzoic acid derivatives. Further SAR studies 
showed that the new scaffold containing an aminobiphenyl moiety (15: IC50 = 10 nM), 
although 20-fold less potent than its methyl ester counterpart 14, was more active in 
vivo. Compound 15, at twice daily 50 mg/kg doses, caused a suppression of 
parasitaemia in mouse blood within 45 days. Survival of mice treated with 15 was > 100 
days whereas control mice died within 20 days. The authors suggested that the 
phenylbenzylimidazole moiety dominates the interaction with P-45014DM resulting in 
inhibition of the enzyme and consequent anti-parasitic activity. However, no data of 
enzymatic inhibition was reported. 
 
2.2.2. Protein farnesyl transferase inhibitors 
Protein prenylation by attachment of polyisoprenoids to specific proteins is 
involved in signal transduction and anchorage of protein to cell membranes. Protein 
farnesyl transferase (PFT) inhibitors are potent antitumor agents in experimental 
animals [58,59] and few molecules have been assayed in phase II clinical trials for the 
treatment of human malignancies [60]. Different studies have demonstrated the 
existence of this process in trypanosomatids and validated PFT inhibitors as an 
antitrypanosomal chemotherapeutic target [13,61]. T. brucei and T. cruzi PFT have been 
cloned and their homology to human and rat orthologues compared. This study revealed 
significant differences between the active site of T. brucei PFT and its mammalian 
counterpart (i.e. rat enzyme), suggesting that selective inhibition of the parasite enzyme 
was possible [61]. For these reasons, PFT inhibitors, whose medicinal chemistry and 
pharmacokinetics are well defined already, have potential to become interesting 
antitrypanosomal molecules.  
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In 2001, the group of Mark Field from the Imperial College of Sciences, 
Technology and Medicine (UK) disclosed, for the first time in a patent, the use of PFT 
inhibitors to treat protozoan parasitic diseases [218]. This patent described the use of 
Manumycin A (16, Figure 4), a Ras farnesyltransferase inhibitor and natural antibiotic 
extracted from cultures of Streptomyces sp., as well as other synthetic cyclic hexenone 
compounds as PFT inhibitors active against T. brucei. Nine compounds were 
specifically claimed for use but no synthetic procedure was disclosed. Some evidences 
suggested that these hydrophobic molecules accumulate to toxic levels into cellular 
membrane. The most potent compound (17, Figure 4) killed > 95 % of bloodstream 
form T. brucei parasites in vitro at a concentration < 5.6 µM (LD50 = 1.5 µM) whereas 
Manumycin A (16) had a LD50 value of 2.5 µM. In this series, the presence of the 
benzoquinone structure resulted in higher toxicity compared to a hydroxyl group.  
Schering Corporation disclosed recently 21 specific PFT inhibitors based on a 
N-(benzo[5,6]cyclohepta[1,2]pyridin-11-yl)piperazine (18) or piperidine scaffold for the 
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treatment of T. brucei infection [219]. The compounds were claimed to inhibit T. brucei 
PFT with an IC50 value between 0.0019 µM and 15 µM in a Scintillation Proximity 
Assay. In vitro growth inhibition of T. brucei ranged between 0.2 µM to < 10 µM. 
 
2.3. DNA modulating agents (DNA binders, Tubulin inhibitors) 
 The most promising patent in term of near-future outcome for the treatment of 
African trypanosomiasis was disclosed by D. Boykin and colleagues in 2004 [220]. This 
application, which claimed the use of dicationic 2,5-diarylfuran aza-analogues for the 
treatment of HAT and malaria, refers to a recent paper published by the same group in 
2003 [62]. Aromatic diamidines have broad spectrum antimicrobial activity and many 
of these aromatic dicationic compounds bind to DNA minor groove at AT-rich sites 
[63,64,65,66,67,68,69,70]. This is the case of drugs such as pentamidine or berenil for 
instance. The antimicrobial action of diamidines is thought to be the result of inhibition 
of different DNA dependent enzymes [71,72]. The molecules disclosed by Boykin and 
colleagues are analogues of DB-289 [2,5-bis(4-amidinophenyl)furan-bis-O-
methylamidoxime], an oral diamidoxime prodrug of furamidine [2,5-bis(4-
amidinophenyl)furan, 19, Figure 5], which is currently being developed by Immtech as 
a potential treatment for Pneumocystis carinii pneumonia, tuberculosis, sleeping 
sickness and malaria. DB-289 (20, Figure 5) is currently in phase II clinical trial for 
stage I African trypanosomiasis [9,10,24,25,26,73]. In this series, different aza-
derivatives and their respective amidine prodrugs (amidoxime, methoxime, and 
ethoxime) were synthesised and the compounds tested in vitro against T. b. rhodesiense. 
The in vivo oral bio-availability in the virulent STIB900 T. b. rhodesiense mouse model 
was also tested. Seven compounds showed IC50 values in the low nanomolar range (IC50 
for furamidine and pentamidine are 4.5 and 2.2 nM, respectively). Compound 21 and its 
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methoxime prodrug 22 had IC50 values of 7.0 and 37.1 nM, respectively (Figure 5). 
Both of these molecules also cured the STIB900 strain of T. b. rhodesiense in a mouse 
model and the methoxime prodrug 22 yielded parasite free mice in the CNS model 
through day 120. As a whole, the methoxime prodrug was consistently more active than 
the amidoxime and aza-analogues showed superior oral activity in vivo compared to 
furamidine analogues [62]. Compound 22 was claimed to be useful as an oral treatment 
of CNS stage HAT [220]. A scalable and more economic procedure for the synthesis of 
DB-289 and related bis-aryl diamidoxime derivatives was disclosed in another patent by 
the same group. This methodology used 2,5-bis-trialkylstannanes and a one step 
palladium-catalyzed cross reaction to form the products [221].  
“Reversed amidines” and guanidine analogues of furamidine were claimed for use as 
antifungal and antimycobacterial infections. The synthesis, DNA binding affinity [i.e. 
melting temperature difference: ∆Tm for poly dA·dT and the dodecamer 
d(CGCGAATTCGCG)2] and antimicrobial activity of nineteen 2,5-di(4-
iminomethylaminophenyl)furan [74], thiophene or pyrrole derivatives was also 
disclosed [222]. In general, both guanidines and reversed amidines had strong DNA 
binding affinities (∆Tm for d(CGCGAATTCGCG)2 oligomer: from 0 to 15.4 compared 
to 11.7 for the parent compound 19), although a terminal pyridyl group lowered such 
affinity as compared to its phenyl counterpart. The specified compound (23, Figure 5) 
showed MIC value ≤ 1.94 µM against C. albicans and MIC 80% values of 1.51 to 97 
mM against six other microbial species (Aspergillus flavus, Aspergillus fumigatus, 
Fusarium solani, Rhizopus arrhizus, Cryptococcus neoformans). These compounds 
were also evaluated against trypanosomes in vitro. The (arylimino)aminophenyl furans, 
especially the (2-pyridylimino)aminophenyl derivatives,  were claimed to be effective 
against T. b. rhodesiense in the 0.039 to 0.194 µM range, meaning a 10-fold lower 
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activity than pentamidine and furamidine in the same assay. On the contrary, these 
compounds were significantly more potent than pentamidine and furamidine against T. 
cruzi, with an activity comparable to that of benznidazole. However, no specific data 
was reported in the patent [222]. Detailed biological data on the activity of these 
dicationic derivatives against T. cruzi and L. donovani was reported in 2003 [69]. The 
most active molecules belong to the reversed amidine series, with the most potent 
compound against T. cruzi having an IC50 value of 0.15 µM (24, Figure 5) with a 
selectivity index (SI) of 48. 
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Figure 5. DNA modulating agents 
 
Kinetoplastid tubulin has been proposed as a potential target against Leishmania 
and trypanosome species and started being exploited for the development of new drugs 
few years ago [75,76,77]. The synthesis, antimicrotubule activity and in vitro 
cytotoxicity of analogues of the antimitotic dinitroaniline sulfonamide herbicide 
compound, oryzalin (3,5-dinitro-N4, N4-di-n-propylsulfanilamide), was recently 
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described by Bhattacharya and co-workers [223,78,79,]. Six compounds were claimed 
among which the most potent analogue, N1-phenyl-3,5-dinitro-N4, N4-di-n-
propylsulfanilamide (GB-II-5, 25, Figure 5), was a selective antimitotic agent against L. 
donovani and T. brucei tubulin. This molecule displayed also potent and selective in 
vitro inhibitory activity against T. b. brucei variant 221 (IC50 = 0.41µM) and T. b. 
brucei Lab 110 EATRO (IC50 = 0.58 µM) [76]. The recent preparation of thirty new 
analogues of GB-II-5 with variations at the N1 and N4 positions allowed the discovery 
of a more potent  derivative, N1-phenyl-3,5-dinitro-N4,N4-di-n-butylsulfanilamide (26), 
which displayed antimitotic activity in cultured T. b. brucei (IC50 = 6.9 µM, 
accumulation of parasites in the G2M cell cycle phases). In general, the most active 
compounds against purified leishmanial tubulin were also the most efficient against L. 
donovani and T. b. brucei in vitro [79]. Despite their good in vitro activity, these 
compounds failed to cure mice infected with T. b. brucei STIB795 parasites at 4×20 
mg/kg ip dose. Thus, issues regarding pharmacokinetics and possible toxicity due to 
nitroaromatic groups need to be addressed in order to fully assess the potential of these 
molecules. 
 
2.4. Purines and pyrimidine metabolism 
 Purine and pyrimidine nucleotides are essential bricks for the synthesis of DNA 
and RNA. Trypanosomes, unlike their mammal hosts, lack of de novo purine 
biosynthesis pathway. Hence, they are dependent on purine salvage from their host 
medium in order to get these building blocks essential for their survival [80]. An 
important enzyme of the purine salvage pathway that has been used as a potential target 
for chemotherapy is hypoxanthine-guanine phosphoribosyl transferase (HGPRT) [13]. 
The potential of allopurinol (4-hydroxypyrazol-[3,4-D]pyrimidine) and derivatives to 
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act as a “subversive substrate” of this enzyme was discovered by Marr and colleagues 
[81,82]. More attention has been paid recently to the potential of pyrimidine metabolism 
as chemotherapeutic target in parasites. Trypanosomes are able to synthesise uridine 5’-
triphosphate nucleotide (UTP) de novo and by salvage of uracil. The enzyme dUTPase 
(deoxyuridine 5’-triphosphate nucleotide-hydrolase), which catalyses hydrolysis of 
dUTP to dUMP and pyrophosphate, is essential for the biosynthesis of dTTP (from 
UMP via thymidylate synthase) and for maintaining the integrity of genomic DNA [83]. 
Trypanosomal dUTPases possess a distinct tridimensional structure and have been 
proposed as potential targets for chemotherapy [83,84]. Recently, a series of triphenyl 
deoxyuridine derivatives selective for plasmodium dUTPase and with in vitro 
antimalarial activity were described [85].  
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Figure 6. CTP synthetase inhibitors 
 
CTP synthetase is another enzyme of the pyrimidine biosynthesis pathway that 
had not been studied in T. brucei until the Hofer and co-workers 2001 paper was 
published [86]. This study showed that the low levels of CTP found in T. brucei were 
the result of slow de novo synthesis and the lack of salvage pathways, making the 
inhibition of this enzyme a potential target for chemotherapy. The use of CTP 
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synthetase inhibitors such as 6-diazo-5-oxo-L-norleucine (DON: 27, Figure 6) and α-
amino-3-chloro-4,5-dihydro-5-isoxazolacetic acid (acivicin: 28) provoked a reduction of 
CTP levels and blocked the growth of T. b. brucei in vitro and in vivo. DON also 
inhibited the growth of bloodstream forms T. b. rhodesiense in vitro (IC50 = 0.36 µM).  
The in vivo assays with both compounds showed a relapse of trypanosomes after the 
treatment was stopped, making the authors suggest that these molecules only block the 
proliferation of the parasites and that an immune response may be required to eradicate 
the parasites. A patent related to this invention was disclosed by these authors [224]. 
They claimed the use of a combination of a CTP synthetase inhibitor, such as a 
glutamine analogue, and a nucleobase (hypoxanthine, adenine or guanine) able to 
alleviate the toxic effects thereof in vivo, for the treatment of malaria, leishmaniasis, 
Chagas’ disease and sleeping sickness. The combination of DON (27) and hypoxanthine 
was preferred.  
 
3. Natural product derived chemotherapeutic agents 
 Natural products derived from plants and animals continue being the major 
source of medicines for man and the basis of many pharmaceutical drugs. In the area of 
tropical medicine in particular, widely used antiprotozoal drugs derive from natural 
products. Quinine, an alkaloid extracted from the cinchona trees (Rubiaceae) found in 
South America and the East Indies, and artemisinin, a sesquiterpene lactone from 
Artemisia annua (Asteraceae) have been used by traditional medicine to treat malaria. 
Many synthetic derivatives of these natural compounds were developed over the 
decades and allowed the discovery of new antiprotozoal drugs with better drug-like 
profiles. In the recent literature, nine patents claiming for use of natural extracts or 
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synthetic natural product derivatives against Chagas’ disease 
[225,226,227,228,229,230] and/or sleeping sickness [230,231,232] were found. 
 
3.1. Quinoline derivatives 
Naphtylisoquinoline alkaloids isolated from African plants (Ancistrocladaceae 
and Dioncophyllaceae families) have shown promising antiprotozoal activity, especially 
against Plasmodium species (e.g. dioncophylline C), T. b. brucei and T. b rhodesiense 
(e.g. dioncophyllines A, B and E) [87,88,89]. University of Mainz disclosed the 
preparation of a series of 3,3-dimethyl-isoquinoline compounds derived from these 
naturally occurring naphtylisoquinolines but lacking of the asymmetric substituents in 
C-1 and C-3 of the ring (29, Figure 7). These modifications made the synthesis of 
analogues much easier. The in vitro activity on T. cruzi infected L6-cells of four 
compounds was presented with IC50 values ranging from 10.6 (29) to 50.3 µM. The 
specified compound [3,3-dimethyl-6-methoxy-8-hydroxy-3,4-dihydroisoquinoline, 29] 
also displayed selectivity (SI > 40) towards the parasite with cytotoxicity on L6-cells > 
439 µM [226]. These compounds were also claimed to be potentially useful for the 
treatment of neurodegenerative diseases based on their glutamate receptor antagonistic 
activity. The same team described a series of chiral 1-phenyl-2-aminomethyl-naphtalene 
derivatives for the same indications [225]. The activity of seven compounds was 
disclosed, being trifluoromethanesulfonate derivative 30 the most interesting one in 
terms of activity (IC50 = 1.9 µM) and selectivity (SI > 36). 
Antidesmone (31) [(S)-4,8-dioxo-3-methoxy-2-methyl-5-n-octyl-1,4,5,6,7,8-
hexahydroquinoline], is an isoquinoline alkaloid extracted from several species of 
Antidesma and Hyeronima (Euphorbiaceae) [90,91]. The in vitro activity against T. 
cruzi, T. brucei, L. donovani and P. falciparum of antidesmone as well as nine 
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tetrahydroisoquinoline and 1,4,5,6,7,8-hexahydroisoquinoline derivatives was claimed 
by the Institüt Für Pflanzenbiochemie [Note: the C-2 stereochemical configuration of 
these derivatives is the opposite to the stereochemistry of the natural product]  [227]. 
IC50 values against T. cruzi were high in general and ranged from 0.02 (compound 32, 
SI > 8000) to 31.6 µM. In comparison, antidesmone (31) and benznidazole had IC50 
values of 0.113 (SI > 1500) and 2.29 µM (SI > 1500), respectively. On the contrary, 
trypanocidal activity of antidesmone on T. b. rhodesiense and T. b. evansi was low (IC50 
= 14.3 and 6.1 µM, respectively) compared to that of melarsoprol (0.0032 and 0.0042 
µM, respectively). 
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Figure 7. Natural product derivatives 
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3.2. Miscellaneous 
In a 2004 patent, the Institut de Recherche pour le Développement disclosed the 
use of canthin-6-one (33), extracted from a Zanthoxylum chiloperone of the 
angustifolium variety, for the treatment of T. cruzi infections [229]. Canthin-6-one had 
been previously tested against P. falciparum [92] or Leishmania spp.  [93] but its 
trypanocidal activity had never been reported. This application shows that this natural 
product is a highly effective trypanocide in the mouse model of Chagas’ disease. 
Canthin-6-one was assayed in chronic and acute mouse models by oral and sub-
cutaneous administration. In the model of acute T. cruzi infection, in a 15 days 
treatment at an oral dose of 5 mg/kg/day (n = 7), canthin-6-one was more effective than 
benznidazole (50 mg/kg/day po, n = 8) at day 15 post-treatment and, contrary to 
benznidazole, the parasites were eradicated at day 68. In the chronic mouse model, in a 
20 days treatment at 5mg/kg/day po, canthin-6-one was again more effective than 
benznidazole (50 mg/kg/day) after a 79 days post-treatment follow-up. The mice treated 
with canthin-6-one (n = 8) were parasite free and protected from death [229]. 
Lignans obtained from leaves of Zanthoxylum naranjillo or Piper cubeba such 
as (-)-cubebin, (-)-methylpluviatolide [94], and semi-synthetic dibenzylbutyrolactonic 
derivatives were claimed as useful for the treatment and prophylaxis of Chagas’ disease 
[228]. The process to obtain these compounds was disclosed and the in vitro anti-
Chagas disease evaluation of seven compounds was reported (Figure 7). In an assay 
with blood trypomastigotes of T. cruzi IC50 values ranged from 2.54 (35), 3.5 (34) to 
274 µM (cubebin). Three compounds which displayed 100% inhibitory activity in vitro 
at 135 µM [O-acetyl cubebin, (-)-methylpluviatolide and (-)-O-(N,N-
dimethylaminoethyl) cubebin] were claimed to show chemo prophylactic ability into 
healthy mice. In a recent study, (-)-hinokinin (35) was shown to have also a potent 
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activity (IC50 = 0.7 µM) in vitro against free amastigote forms of Trypanosoma cruzi 
[95]. 
University of California disclosed a method for the isolation and purification of 
marine pseudopterosin compounds from Symbiodinium spp. symbionts, preferably 
obtained from the coral Pseudopterogorgia elisabethae [230]. This method has the 
advantage of using a non-animal source for the production of these molecules. 
Pseudopterosin A (36) is one of the 18 pseudopterosin compounds specifically claimed 
for preparation and for use as chemotherapy. However, no biological data was reported 
for that application.  Another class of natural products derived from marine sponges, 
manzamine alkaloids, were claimed for use in the treatment of drug-resistant infections 
including malaria and sleeping sickness [232]. Several semi-synthetic derivatives 
prepared from manzamine A were described. Manzamine A and (-)-ENT-8-
hydroxymanzamine A (37) had IC50 values in the range 0.008 to 0.014 µM against P. 
falciparum and SI values of 36 and 40 , respectively. Both molecules also exhibited in 
vivo activity against P. berghei greater than chloroquine or artemisinin [96].  No 
biological data regarding trypanocidal activity was disclosed.   A recent patent from 
Nereus Pharmaceuticals Inc. [233] claimed the use of [3.2.0] heterocyclic compounds 
analogues of the marine natural product salinosporamide A as proteasome and NF-κB 
inhibitors for the treatment of neoplasm, inflammation and microbial infection. 
Salinosporamide A (38) had a mean GI50 value of 10 nM against 60 tumor cell lines and 
also inhibited proteasome activity with an IC50 value of 11.8 nM (NF-kB activity of 
HEP293 cells). No biological data of antitrypanosomal activity was disclosed. This 
claim is based on the well-known potential of proteasome inhibitors against 
trypanosomes in vitro [28,97].  
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4. Single synthetic entities 
This section includes patents describing the synthesis and screening of 
compounds against several pathogenous agents, including protozoa. No specific targets 
were claimed to explain the trypanocidal activity of these molecules.  
Bicyclic carbohydrates for the treatment of parasitic diseases such as leishmaniasis and 
trypanosomiasis were disclosed by Kemin Pharma Europe [234]. Three compounds 
were specifically claimed. Their synthesis and in vitro activity against T. b. rhodesiense, 
T. cruzi, P. falciparum and L. donovani was disclosed. One compound (39, Figure 8) 
was active against T. b. rhodesiense trypomastigotes (IC50 = 0.187 µM vs. 0.21 µM for 
suramin) and displayed selectivity vs. human MRC-5 cells (SI > 171). The other two 
compounds had IC50 values of 1.01 and < 0.98 µM against L. donovani amastigote 
infected macrophages, respectively.   
The synthesis and in vitro T. cruzi activity of a series of 4-bromophenyl derivatives was 
disclosed by the Universidade Estadual de Campinas in Brazil [235]. The furanyl 
derivative (40) showed interesting trypanocidal activity against T. cruzi (IC50 = 9.5 
µM). Merck & CO Inc. disclosed a series of novel imidazo[1,2-a]pyridines (41) and N-
oxides derivatives claimed to be useful for the treatment and prevention of protozoan 
infections, particularly African trypanosomiasis, Chagas’ disease, malaria and 
toxoplasmosis [236]. Representative synthesis for the final compounds was given in 8 
examples but no relevant biological data were presented. 
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Figure 8. Single synthetic entities 
 
5. Expert opinion 
Trypanosomiases affect millions of people in Africa and South America and kill 
around 60,000 people annually. The economic burden for affected countries is huge and 
represent 1 598 000 and 649 000 DALYs (Disability Adjusted life-years) for sleeping 
sickness and Chagas’ disease, respectively [98]. Nevertheless, they are among the most 
neglected diseases in the world. The drugs available for the treatment of these diseases 
are far from satisfactory (e.g. low effectiveness, toxicity, high price, mode of 
administration, increasing treatment failures) and there is currently no drug able to cure 
chronic Chagas’ disease. These diseases are totally neglected by pharmaceutical 
companies because of the low income of affected countries and the low financial return 
expected. For these reasons, the search for new antitrypanosomal drugs relies almost 
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exclusively on public research funded by governments and not-for-profit organisations, 
or on public-private partnerships in a few cases [99]. If we refer to the patents reported 
in this review, it seems, at first sight, that antitrypanosomal research is shared between 
industry (18 patents) and academia (18 patents). However, a deeper look at these trends 
reveals the true fact: most industry patents reporting possible trypanocidal activity are 
targeting other human diseases (e.g. cysteine protease inhibitors for the treatment of 
various cancers and bone diseases) and most patents claiming specifically 
antitrypanosomal activity (as the main claim) belong to the academia. Hence, industry 
patents lack, in general, of specific biological data (only found in 8 patents) supporting 
their claims for antitrypanosomal chemotherapeutic potential. Thus, it appears that 
pharmaceutical companies have libraries of synthetic compounds patented as possible 
antitrypanosomal agents but not tested as such, probably because of the low financial 
return expected. If academia could get the financial resources and industry agreement to 
run the biological screening of these compounds against trypanosomes (e.g. in a WHO-
TDR granted screening centre), new antitrypanosomal lead compounds would probably 
emerge from such collaboration. There is a real need for academia-industry partnership 
in order to get enough financial backing for projects aimed at the discovery of new 
chemotherapeutic drugs against these diseases.  
Thanks to financial backing from the Gates Foundation and the Drug for 
Neglected Diseases (DNDi) initiative from Médecins sans Frontières (MSF), one drug, 
the diamidine prodrug DB289, is currently in the bottleneck for the oral treatment of 
first stage sleeping sickness. This drug, which successfully finished a phase IIa clinical 
trial in first-stage T. b. gambiense sleeping sickness patients, is also being investigated 
in preclinical studies on an African green monkey model for second-stage disease [73]. 
DB289 and its aza-analogues [220] are at the moment the most promising 
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antitrypanosomal drugs in development for sleeping sickness. No other new drugs are 
currently in clinical trial for HAT or Chagas’ disease. Hence, a pragmatic approach for 
the rapid development of new antitrypanosomal chemotherapy would be the clinical 
assessment of drug combination with existing trypanocides. 
Despite being among the most studied parasites from a biological point of view, 
trypanosomes remain a challenge for chemotherapy. The growing knowledge of the 
parasite biochemistry has open the way to new chemotherapeutic approaches based on 
newly validated biochemical targets [100]. A number of patents have appeared which 
dealt with new targets and disclosed interesting in vitro activity against T. cruzi (e.g. 
CPIs, sterol biosynthesis inhibitors) or T. brucei (e.g. PFT inhibitors, tubulin inhibitors, 
CTP synthetase inhibitors). However, only a few exciting in vivo results were reported 
among which the rationally designed C14-demethylase inhibitors (15) of Yale 
University, with an excellent potential against T. cruzi [217]. As usually happens in 
medicinal chemistry, natural products furnished another source of interesting lead 
compounds (30 and 32) with excellent in vitro activity and also exciting in vivo cures 
(32) of an acute and chronic mouse model of T. cruzi infection [227,229]. In this sense, 
screening of natural products and other in-house libraries of synthetic compounds 
against trypanosomes should allow to discover new trypanocidal lead compounds [101]. 
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